Showing results (321-330 of 454) with videos related to
Sort By:
Pageof 46
The New England Journal of Medicine|October 22, 2025
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast CancerJavier Cortés, Kevin Punie, Carlos Barrios, et al.Medicina (Kaunas, Lithuania)|July 29, 2023
Does Surgical Approach Influence Complication Rate of Hip Hemiarthroplasty for Femoral Neck Fractures? A Literature Review and Meta-AnalysisMatteo Filippini, Marta Bortoli, Andrea Montanari, et al.Frontiers in Oncology|February 6, 2023
Assessing the pathogenicity of BRCA1/2 variants of unknown significance: Relevance and challenges for breast cancer precision medicineElisa De Paolis, Ida Paris, Bruno Tilocca, et al.Environmental Research|November 29, 2025
Bisphenol A triggers adipocyte dysfunction, thereby fostering triple-negative breast cancer aggressivenessAnna Citarella, Tanja Milena Autilio, Zein Mersini Besharat, et al.Journal of Clinical Medicine|July 13, 2024
Long-Term Safety of Level II Oncoplastic Surgery after Neoadjuvant Treatment for Locally Advanced Breast Cancer: A 20-Year ExperienceAlejandro M Sanchez, Flavia De Lauretis, Angela Bucaro, et al.Journal of Neuro-Oncology|April 22, 2014
IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapyGiuseppe Minniti, Claudia Scaringi, Antonella Arcella, et al.International Journal of Molecular Sciences|June 10, 2023
Investigating the Inhibition of FTSJ1, a Tryptophan tRNA-Specific 2'-O-Methyltransferase by NV TRIDs, as a Mechanism of Readthrough in Nonsense Mutated CFTRPietro Salvatore Carollo, Marco Tutone, Giulia Culletta, et al.Healthcare (Basel, Switzerland)|December 30, 2025
A New Model for Bone Health Management in Postmenopausal Early Breast Cancer Patients Undergoing Adjuvant Endocrine Therapy-The Predict & Prevent ProjectStefania Gori, Alessandra Fabi, Rossana Berardi, et al.Current Oncology (Toronto, Ont.)|August 27, 2025
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with DenosumabAngelachiara Rotondi, Valentina Frescura, Giorgia Arcuri, et al.International Journal of Cancer|November 15, 2019
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trialMatteo Lambertini, Francesca Poggio, Marco Bruzzone, et al.Pageof 46